CSL (CSL.AX) Aandeel Koers
CSL Koers
De omzet is de afgelopen 19 jaar met 8,9% per jaar gegroeid tot 16,04 Miljard USD. De winst per aandeel is de afgelopen 18 jaar met 11,8% per jaar gegroeid. De nettowinstmarge van CSL ligt op -16,4% en is ten opzichte van 21,5% enkele jaren eerder gedaald. CSL biedt momenteel een dividendrendement van circa 2,93%. De uitkeringsratio ligt rond 53% van de winst. Het dividend is de afgelopen 19 jaar met 12,7% per jaar gegroeid. Analisten hanteren een mediaan koersdoel van 143,65 USD — dat impliceert 12,3% boven de huidige koers. Van de 20 analisten geven 15 het aandeel een koopadvies — per saldo een Kopen-consensus.
CSL aandeelkoers
CSL bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over CSL
The business model of CSL Ltd is focused on providing innovative biotherapies and pharmaceutical products to patients worldwide. With a strong commitment to research and development, CSL specializes in developing plasma-derived and recombinant therapies for various medical conditions. The company's portfolio includes immunoglobulins, vaccines, and coagulation factors, among others. CSL operates through its two main business segments, CSL Behring and Seqirus. CSL Behring focuses on developing and manufacturing therapies for rare and serious diseases, while Seqirus is dedicated to producing influenza vaccines. CSL Ltd's business model emphasizes delivering high-quality and life-saving treatments to improve the health and well-being of individuals globally.
CSL Ltd is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of CSL Ltd in the market are Biogen Inc., Grifols S.A., and Shire Plc.
CSL Ltd, also known as CSL Limited, is a global biotechnology company headquartered in Australia. Established in 1916, CSL has a rich history of over a century. Originally known as the Commonwealth Serum Laboratories, it transitioned into a private company in 1994. CSL specializes in the research, development, manufacturing, and marketing of innovative biotherapies and vaccines to combat serious medical conditions. With a strong commitment to improving public health, CSL has expanded its operations globally and has become a trusted name in the biopharmaceutical industry. Today, CSL Ltd continues to make significant contributions to healthcare worldwide through its advanced technologies and dedicated team.
CSL Ltd, a renowned Australian biotechnology company, has achieved numerous significant milestones throughout its history. Notably, CSL Ltd successfully developed and marketed first-of-its-kind blood plasma products and vaccines. They introduced the world's first recombinant product derived from human genes, being pivotal in the treatment of hemophilia. CSL Ltd has also made groundbreaking advancements in the field of immunoglobulins, leading to innovative therapies. Furthermore, the company expanded its global presence and became a major player in the biopharmaceutical industry. With its dedication to research, development, and revolutionizing healthcare, CSL Ltd continues to make remarkable contributions to the medical field.
CSL Ltd is primarily present in various countries and regions across the globe. These include Australia, the company's home country where it is headquartered, North America, Europe, and Asia-Pacific. With a strong global presence, CSL Ltd has established itself as a leading biotechnology company, providing innovative and life-saving solutions in the areas of vaccines, plasma therapies, and recombinant products. As a multinational corporation, CSL Ltd has successfully expanded its operations and collaborations internationally, further strengthening its position in the global market.
CSL Ltd represents strong values and a dedicated corporate philosophy. As a global biotechnology company, CSL is committed to enhancing the health and well-being of people worldwide. The company strives for excellence in its operations, focusing on innovation, quality, and patient-centric outcomes. CSL upholds integrity, ethics, and transparency in all aspects of its business, fostering trust with stakeholders. With a mission to save lives and improve patient outcomes, CSL maintains a customer-driven approach, continuously working towards breakthroughs in medical research and development. Through its commitment to these values and corporate philosophy, CSL Ltd demonstrates its dedication to making a positive impact on global healthcare.
Analisten hanteren momenteel een gemiddeld koersdoel van 152,89 USD voor het aandeel CSL (mediaan: 143,65 USD), oftewel +19,5 % ten opzichte van de laatste koers. De consensus is gebaseerd op 20 analistenratings.
20 analisten beoordelen het aandeel CSL momenteel: 13 adviseren kopen, 7 houden en 0 verkopen.
Omgezet tegen de huidige wisselkoers noteert het aandeel CSL op 114,18 EUR (127,95 USD).
Het aandeel CSL (CSL.AX) is genoteerd aan 7 beurzen, waaronder: SIX (Zürich) (CSL.SW), ASX (CSL.AX), Frankfurt (CSJ.F), München (CSJ.MU), Düsseldorf (CSJ.DU), Hamburg (CSJ.HM).
CSL is a global biotechnology company focused on the production of plasma and vaccine products. The company is divided into two divisions: CSL Behring and Seqirus. CSL Behring produces plasma derivatives used to treat life-threatening diseases and disorders such as Alpha-1 antitrypsin deficiency, bleeding disorders, and immune deficiencies. CSL Behring is the third largest producer of plasma derivatives worldwide with production facilities on five continents. Seqirus is the vaccine division of CSL and focuses on the research, development, manufacturing, and marketing of influenza vaccines. The company is the second largest producer of influenza vaccines globally and has production facilities worldwide. Additionally, CSL also produces products in the field of immunosuppression and inflammatory diseases. The company prides itself on meeting some of the highest quality standards in the industry and collaborate closely with patient organizations to promote understanding of the importance of plasma derivatives and vaccines. CSL's business model is based on the research, development, and production of biological products to treat and prevent life-threatening diseases and disorders. CSL's plasma derivatives and vaccines are often life-saving and essential for the health and lives of many people. CSL invests significantly in research and development to develop and improve new products and treatments. The company works closely with government agencies and health organizations to ensure that its products meet the highest standards and are accessible worldwide. To further strengthen its business model, CSL has developed a long-term growth strategy based on innovation, capacity expansion, and geographic expansion. The company will continue to invest in new technologies and research and development to meet the growing demand for life-saving products and treatments. In summary, CSL is a global biotechnology company focused on the production of plasma derivatives and vaccines. The company has two main divisions, CSL Behring and Seqirus, and also produces products in the field of immunosuppression and inflammatory diseases. The business model is based on research, development, and production of biological products to treat and prevent life-threatening diseases and disorders. The company invests significantly in research and development to develop and improve new products and treatments and has developed a long-term growth strategy to meet the growing demand for life-saving products and treatments.
De omzet van CSL bedraagt 16,04 Miljard USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De winst van CSL bedraagt -2,64 Miljard USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van CSL bedraagt momenteel -23,25. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het CSL-aandeel in te schatten.
De koers-omzetverhouding (P/S) van CSL bedraagt momenteel 3,82. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het CSL-aandeel.
De Eulerpool Kwaliteitsscore voor CSL is 6/10.
De ISIN van CSL is AU000000CSL8. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van CSL is 890952. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van CSL is CSL.AX. Onder dit beurstickersymbool wordt het CSL-aandeel op de beurs verhandeld.
CSL aandeel
CSL Peer Group
CSL Ticker
CSL FIGI
Alle fundamentals en diepgaande analyse van CSL
Onze aandelenanalyse van het CSL-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van CSL. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: